Wound healing outcomes in diabetic kidney disease patients receiving SGLT2 inhibitor therapy: a prospective propensity score-matched cohort study - Takeaways - MDSpire

Wound healing outcomes in diabetic kidney disease patients receiving SGLT2 inhibitor therapy: a prospective propensity score-matched cohort study

  • By

  • Rong-rong Zhang

  • Siyue Huang

  • Xinjie Wang

  • Xiaoqin Li

  • June 3, 2026

  • 0 min

Share

  • 1

    This study enrolled 247 adults with type 2 diabetes and diabetic kidney disease to evaluate wound healing outcomes with SGLT2 inhibitors.

  • 2

    After matching, 204 patients were analyzed, showing similar median healing times of 33 days for SGLT2 users and 34 days for controls.

  • 3

    No significant differences in wound infection rates were found between SGLT2 inhibitor users and controls during the study.

  • 4

    SGLT2 inhibitor users demonstrated no renal progression events and better eGFR preservation compared to the control group.

  • 5

    The findings suggest that SGLT2 inhibitors do not impair wound healing or increase infection risk in patients with diabetic kidney disease.

Original Source(s)

Wound healing outcomes in diabetic kidney disease patients receiving SGLT2 inhibitor therapy: a prospective propensity score-matched cohort study

  • by Rong-rong Zhang, Siyue Huang, Xinjie Wang, Xiaoqin Li

  • June 3, 2026

Related Content

A FAERS database study on visual impairment adverse events associated with three long-acting insulin analogues

Retinal Age as Disease Biomarker

Fundus-based AI screening can indicate “retinal age” of patients, as well as flag systemic disease risks, says new study

  • May 27, 2026

  • 3 min
Assessment of Two-Phase Diagnostic Timelines in Diabetic Retinopathy and Contributing Factors: A Cross-Sectional Analysis